XBIO - Xenetic Biosciences, Inc. Quarterly EPS earnings growth

Xenetic Biosciences, Inc. - graphic logo of issuer XBIO

Xenetic Biosciences (XBIO) is currently in the pre-commercial stage, relying on grants and equity issuance without direct revenue. The strategy is based on licensing biopharmaceutical drug delivery platforms to industry behemoths. The quarterly EPS change scale confirms the current development vector, where the -119.20 mark serves as a key metric. This reinforces the potential of DNase therapy, which breaks down tumor defenses to enhance immunity and chemotherapy.

XBIO: xeneticbio.com Year-over-year earnings per share growth for the last 12 months 07/04/2022 - 11/18/2026

Comprehensive metric breakdowns and analytics for xeneticbio.com (XBIO)

- market value and analyst target forecast:
Comprehensive company analysis:Xenetic Biosciences Inc., XBIO
Manufactured product of Xenetic Biosciences

Professional selection of resilient assets is based on comparing net earnings per share growth rates with market forecasts to protect capital. By analyzing quarterly earnings per share trends, an investor assesses the efficiency of value generation, which is critical for Xenetic Biosciences (XBIO) due to rising operating expenses for patents and testing during the pre-commercial scaling period.

Competitor analysis for Xenetic Biosciences

ONC: Quarterly EPS earnings growth|Halozyme Inc. - Year-over-year earnings per one share growth for the last 12 months|RVMD (Revolution Medicines Inc) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Ascentage Pharma Group AAPG|Quarterly EPS earnings growth CGON|Quarterly EPS earnings growth UroGen Pharma Ltd (URGN)|Quarterly EPS earnings growth BCAX (Bicara Corp)|Personalis Genomics (PSNL) - Earnings per share growth in annualized terms for the last twelve months|Erasca Oncology - Quarterly EPS earnings growth|DCTH: Year-over-year earnings per share growth for the last twelve months|YMAB: Quarterly EPS earnings growth|Aura Bio (AURA) - Quarterly EPS earnings growth|CADL (Candel Therapeutics Inc.) - Quarterly EPS earnings growth|ARAY: Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months SLS (SELLAS Life Sciences Group, Inc.)|Year-over-year earnings per share growth rate for the last twelve months ACTU|Citius Oncology - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months HURA|TARA: Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months Fate Pharma|Aadi Bioscience Inc (WHWK) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months TScan (TCRX)|Year-over-year net earnings per share growth for the last 12 months CSBR|xbiotech.com (XBIT) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months cel-sci.com (CVM)|OSTX - Earnings per share growth in annualized terms for the last twelve months|Radiopharm Theranostics - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months ARTV|ANL - Year-over-year earnings per share growth for the last twelve months|VERU - Quarterly EPS earnings growth|Tempest Therapeutics, Inc. (TPST) - Year-over-year earnings per share growth for the last twelve months|XLO: Year-over-year earnings per share growth rate for the last twelve months|RENB (Renovaro Biosciences) - Quarterly EPS earnings growth|MURA: Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months KAPA (Kairos Pharma Ltd)|Year-over-year earnings per share growth rate for the last twelve months OKUR|CytoMed Therapeutics Limited - Year-over-year net earnings per share growth for the last 12 months|CRIS: Year-over-year earnings per share growth for the last 12 months|APLM - Year-over-year earnings per share growth for the last twelve months|THAR - Quarterly EPS earnings growth|ADVB: Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months GNPX|CLDI (Calidi Biotherapeutics, Inc.) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months SBFM|Quarterly EPS earnings growth SLRX|Purple Biotech - Year-over-year earnings per share growth for the last 12 months|American Oncology Network - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months BGNE|CKPT - Year-over-year earnings per share growth for the last twelve months|Elevation Oncology (ELEV) - Year-over-year net earnings per share growth for the last 12 months|ICAD: Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Ikena Oncology Inc.|NTBL (Notable Labs Ltd) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Viracta Therapeutics (VIRX)|Year-over-year earnings per share growth for the last twelve months MorphoSys Corporation (MOR)|NAYA (NAYA Biosciences) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth AAPGV (Ascentage)